Hawaii Moves Forward on Psychedelic Therapy Research Framework

HONOLULU – The Hawaii Senate approved legislation that would set up a state task force to examine ways to bring breakthrough mental health treatments, like psilocybin- and MDMA-assisted therapies, into clinical and policy discussions.

Senate Bill 3199, sponsored by Sen. Chris Lee (D), cleared the chamber on a unanimous 24-0 vote with one senator excused. The measure now heads to the House of Representatives, where it received first reading on March 10 and was referred to the committees on Health and Human Services and Finance.

The bill establishes the Mental Health Emerging Therapies Task Force, which would operate for two years under an entity experienced in scientific research and medical education. It would include 13 members drawn from the state Department of Health, the attorney general’s office, the University of Hawaii’s medical school, the Office of Wellness and Resilience, and individuals with relevant lived experience.

Lawmakers noted that the state faces an urgent mental health challenge, with suicide remaining a leading cause of preventable death, especially among veterans, first responders and trauma survivors. The task force would review existing scientific literature, help expand opportunities for clinical trials and research, recommend professional training programs, study approaches used in other states, and prepare a roadmap for any future implementation that meets standards for safety, ethics and cultural respect.

An interim report would go to the Legislature by early 2027 and a final one by early 2028. The task force would sunset on June 30, 2028. The legislation also directs Hawaii’s Board of Pharmacy to match any federal reclassification of these substances by the Food and Drug Administration within 90 days.

The proposal builds on earlier state efforts, including a 2023 advisory group that looked at similar questions. It reflects a cautious strategy as federal regulators continue to assess these compounds, which have received breakthrough therapy designations for conditions such as treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).

The Senate’s action fits a pattern seen in several states that are laying groundwork for potential federal changes rather than rushing new access programs. Clinical research has produced promising early results for certain hard-to-treat mental health conditions, yet legal classification at the federal level still limits broader use. Hawaii’s emphasis on research partnerships with the University of Hawaii and culturally informed planning could create targeted opportunities for medical studies and professional development without committing resources prematurely.

Image: stock.adobe.com/Asma